Skip to content
Peptigraph home

Sermorelin and Ipamorelin Together: What Is Known

Sermorelin and Ipamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
GHRH analogCompounded by prescriptionSermorelinGHRH analog once FDA-approved as Geref and since discontinued; in an uncontrolled pediatric study mean height velocity rose from 4.1 to 8.0 cm/yr after 6 months.[17]Growth hormoneGHRP (ghrelin receptor agonist)Not FDA approved · research chemicalIpamorelinGhrelin-receptor agonist peptide, not FDA-approved; in a randomized trial after bowel resection, median time to first tolerated meal was 25.3 versus 32.6 hours with placebo.[14]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 5 results, 2 Oct 2026).

Neither is FDA approved for use in people, and we have no sourced data on combining them.
Each component

Side by side

Showing 9 of 13 fields where the two differ. Category, PCAC vote, Jul 2026, WADA, Evidence strength are the same or both unknown.

FieldSermorelinIpamorelin
ClassGHRH analogGHRP (ghrelin receptor agonist)
Also called—ipa, ipam
FDA statusCompounded by prescriptionNot FDA approved · research chemical
Anti-doping detection
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
  • After nasal dosing, ipamorelin metabolites were still found in urine after the parent drug was gone (samples were collected for 2 days).PMID 25869809
  • A direct-urine screen includes ipamorelin among the peptides it can detect, at 50 to 500 pg/mL.PMID 26578461
Half-lifeNo published half-life foundPubMed search, 11 Oct 20262 hours terminal half-lifeintravenous infusion (15 min) · Pharmaceutical research 1999, PMID 10496658
Human studies we summarised6 human (1 randomized or controlled) of 9 summarised2 human (2 randomized or controlled) of 12 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 9 mg, 15 mg2 mg, 5 mg, 10 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)
Related tools

Sold pre-mixed too

Some vials combine these peptides. The blend calculator shows the dose of each component per draw.

Blend calculator

Where sermorelin and ipamorelin come from

In an open-label trial in prepubertal children with GH deficiency, mean height velocity rose from 4.1 cm/yr at baseline to 8.0 cm/yr after 6 months of sermorelin.[17]

The only US maker of recombinant GHRH, EMD Serono, announced the discontinuation of Geref in July 2008.[19]

In animal work, ipamorelin was described as the first GHRP-receptor agonist whose selectivity for GH release is similar to GHRH.[20]

Ipamorelin's human pharmacokinetics come from a dose-escalation study in healthy male volunteers, which found a terminal half-life of 2 hours.[13]

The closest thing to a human stack

A retrospective chart review in 105 men on testosterone therapy used GHRP-6, GHRP-2 and SERM (sermorelin), not ipamorelin. Only 14 men met its strict inclusion criteria.[6]

In those 14 men the average IGF-1 rose from 159.5 to 239.0 ng/mL, a hormone marker rather than a body-composition result.[6]

A PubMed search on 2 Oct 2026 for ipamorelin with sermorelin matched 5 records.

Calculated from pubmed query (ipamorelin[tiab]) AND (sermorelin[tiab] OR Geref[tiab]); records matched 5; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

What the human data cannot show

A review of secretagogues in hypogonadal men calls clinical efficacy data largely lacking for the whole class, sermorelin and ipamorelin included.[21]

The ipamorelin randomised trial cited reported no significant difference from placebo in its key and secondary efficacy analyses.[14]

Common questions

Sermorelin vs ipamorelin: which is better?

No trial compares them. Sermorelin has paediatric growth data and a discontinued brand; ipamorelin has no approved product and one randomised trial with no significant difference from placebo.[14]

Is sermorelin still FDA approved?

Its only FDA records are for Geref, listed as discontinued, and no currently marketed approved sermorelin product was found.[22]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  4. 4Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  5. 5Growth hormone (GH)-releasing hormone-(1-29) twice daily reverses the decreased GH and insulin-like growth factor-I levels in old men.The Journal of clinical endocrinology and metabolism · 1992PMID 1379256Accessed 2 Oct 2026
  6. 6Growth Hormone Secretagogue Treatment in Hypogonadal Men Raises Serum Insulin-Like Growth Factor-1 Levels.American journal of men's health · 2017PMID 28830317Accessed 2 Oct 2026
  7. 7Effects of single nightly injections of growth hormone-releasing hormone (GHRH 1-29) in healthy elderly men.Metabolism: clinical and experimental · 1997PMID 9005976Accessed 2 Oct 2026
  8. 8PubMed search: (sermorelin[tiab] OR Geref[tiab]) (34 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: (sermorelin[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab] OR "GHRH 1-29"[tiab]) AND (elderly[tiab] OR aging[tiab] OR "older adults"[tiab] OR adults[tiab]) AND (treatment[tiab] OR therapy[tiab] OR administration[tiab]) (15 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: (sermorelin[tiab] OR Geref[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11Determination of growth hormone releasing peptides metabolites in human urine after nasal administration of GHRP-1, GHRP-2, GHRP-6, Hexarelin, and Ipamorelin.Drug testing and analysis · 2015PMID 25869809Accessed 2 Oct 2026
  12. 12Simplifying and expanding the screening for peptides <2 kDa by direct urine injection, liquid chromatography, and ion mobility mass spectrometry.Journal of separation science · 2016PMID 26578461Accessed 2 Oct 2026
  13. 13Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers.Pharmaceutical research · 1999PMID 10496658Accessed 2 Oct 2026
  14. 14Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.International journal of colorectal disease · 2014PMID 25331030Accessed 2 Oct 2026
  15. 15The growth hormone secretagogue receptor 1a agonists, anamorelin and ipamorelin, inhibit cisplatin-induced weight loss in ferrets: Anamorelin also exhibits anti-emetic effects via a central mechanism.Physiology & behavior · 2024PMID 39043357Accessed 2 Oct 2026
  16. 16PubMed search: (ipamorelin[tiab]) AND (sermorelin[tiab] OR Geref[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  17. 17Once daily subcutaneous growth hormone-releasing hormone therapy accelerates growth in growth hormone-deficient children during the first year of therapy. Geref International Study Group.The Journal of clinical endocrinology and metabolism · 1996PMID 8772599Accessed 2 Oct 2026
  18. 18PubMed search: (sermorelin[tiab] OR Geref[tiab] OR "GHRH(1-29)"[tiab] OR "GRF(1-29)"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  19. 19Clinical review: Is lack of recombinant growth hormone (GH)-releasing hormone in the United States a setback or time to consider glucagon testing for adult GH deficiency?The Journal of clinical endocrinology and metabolism · 2009PMID 19509104Accessed 2 Oct 2026
  20. 20Ipamorelin, the first selective growth hormone secretagogue.European journal of endocrinology · 1998PMID 9849822Accessed 2 Oct 2026
  21. 21Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males.Translational andrology and urology · 2020PMID 32257855Accessed 2 Oct 2026
  22. 22Drugs@FDA (openFDA) search: active ingredient "sermorelin"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.